The study focuses on two blood‑cell disorders: Chronic Immune Thrombocytopenia (cITP), in which the body destroys platelets that help stop bleeding, and Autoimmune Hemolytic Anemia (AIHA), where the immune system attacks red blood cells, leading to anemia. The investigational therapy is a specially engineered cell product called Zolacabtagene Autoleucel (BMS-986353), also known as Zola‑cel, which belongs to a class of treatments named CD19-Targeted NEX‑T CAR T Cells. These cells are made from a patient’s own immune cells, altered in the laboratory, and then given back through an intravenous (through the vein) infusion; the active ingredient is identified by the code cc-97540. The main goal of the trial is to see whether this therapy is safe, tolerable, and effective in improving blood counts for people with these conditions.
Participants will first undergo screening tests, then receive a single infusion of the modified cells. After the infusion, they will have regular clinic visits where blood samples are drawn and simple health questionnaires are completed to monitor for any side effects and to check if platelet or red‑cell numbers improve. Follow‑up continues for several months to observe how long any benefit lasts and to record any additional medical support needed. Throughout the study, doctors will watch for any unusual lab results or symptoms and will provide standard medical care as needed.
Denmark 
Germany 
